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As with payers in many other countries faced with the reality that the costs of medicines are rising, Cana-da’s public drug plans use health technology assess-
ment to inform reimbursement decision-making.1 Health 
technology assessment is a multidisciplinary field of research 
that generally considers the therapeutic benefits, cost-
effectiveness, and social, ethical and organizational impact of 
a new health technology such as a pharmaceutical, medical 
device, or diagnostic or surgical intervention to inform 
health policy and reimbursement decisions. Although health 
technology assessment is a young field of research, regional 
and national bodies have been active in this area in Canada 
since the 1980s.2,3 Today, CADTH administers the Com-
mon Drug Review program, which conducts a centralized 
national health technology assessment process recognized by 
all public drug plans except Quebec’s. Before the inception 
of the Common Drug Review in 2002, several provincial 
drug plans undertook their own health technology assess-
ment processes to determine coverage for new drug prod-
ucts. CADTH established the Common Drug Review to 
standardize the process in Canada by which health technol-
ogy assessments are conducted to review new drugs and 
make reimbursement recommendations, harmonize deci-
sion-making across different public drug plans, reduce dupli-
cation of work and ultimately decrease the time delay before 
patients can access new medicines.4
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Background: The CADTH Common Drug Review was established in 2002 to prepare national health technology assessment 
reports to guide listing decisions for 18 participating drug plans. The aim of this study was to compare the nonmandatory 
recommendations from the Common Drug Review in Canada with the listing decisions of provincial payers to determine alignment.
Methods: We identified the recommendations issued by the Common Drug Review from Jan. 1, 2009, to Jan. 1, 2015, and compared 
these with the listing decisions of 3 provincial public payers (Alberta, British Columbia and Ontario) that participate in the Common 
Drug Review and the recommendations from Quebec.
Results: We identified 174 medicine–indication pairs in CADTH Common Drug Review reports issued from Jan. 1, 2009, to Jan. 1, 
2015; 110 of these met the inclusion criterion. Among the 110 medicine–indication pairs, listing decisions were available for 95 in 
Alberta, 102 in Quebec, 104 in Ontario and 106 in BC. There was moderate to substantial agreement between provincial listing 
decisions and Common Drug Review recommendations: 74.5% (κ = 0.47, 95% confidence interval [CI] 0.31–0.64) for Quebec, 
78.8% (κ = 0.56, 95% CI 0.41–0.72) for Ontario, 78.9% (κ = 0.58, 95% CI 0.42–0.74) for Alberta and 81.1% (κ = 0.62, 95% CI 
0.47–0.77) for BC.
Interpretation: Our study showed moderate to substantial agreement between Common Drug Review recommendations and 
provincial listing decisions. Future studies can build on this research by evaluating the concordance between Common Drug Review 
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As have many other sources of health technology assess-
ments, the Common Drug Review has been subject to criti-
cism. In 2011, a study reported the degree of agreement 
between the Common Drug Review’s reimbursement recom-
mendations and the listing decisions of 3 provinces to be “no 
better than random chance.”5 However, these findings contra-
dict those of another study.6 In the present study, we con-
ducted a comparison using more recent data and thus our 
findings are more relevant to the current environment of 
health technology assessment and help to determine whether 
the Common Drug Review is creating more standardized cov-
erage for medicines across Canada.7 Morgan and colleagues8 
argued that having multiple provincial decision-makers 
reduces the impact of the Common Drug Review. Similarly, 
Hollis and Law9 predicted that without a national Canadian 
formulary the Common Drug Review would only slightly 
improve the standardization of the coverage of medicines 
across provinces.
The aim of this study was to examine the impact of the 
Common Drug Review by comparing its nonmandatory 
reimbursement recommendations with the final listing deci-
sions of provincial drug plans.
Methods
Study design
All provincial drug plans review new medicines approved by 
Health Canada to determine whether they will be eligible for 
reimbursement, and almost all public drug plans in Canada 
participate in the Common Drug Review. The Common 
Drug Review generates a clinical and economic report for 
each new drug and provides a reimbursement recommenda-
tion to inform decision-making at the provincial level. We 
chose Alberta, British Columbia and Ontario for our analysis 
because they are the 3 most populous provinces with public 
drug plans that participate in the Common Drug Review. 
We also included Quebec because it is the only province that 
does not participate in the national Common Drug Review; 
the Institut national d’excellence en santé et en services 
sociaux (INESSS) conducts health technology assessments 
independently. We used information from the websites of 
CADTH, INESSS and the governments of Alberta, BC and 
Ontario to identify reimbursement recommendations made 
through the Common Drug Review process and INESSS 
and to identify the listing decisions for Alberta, BC and 
Ontario.10–14 The study design for this research followed the 
STROBE Initiative’s recommendations for reporting obser-
vational studies15 (available at www.cmajopen.ca/content/4/4/
E674/suppl/DC1).
Data sources
CADTH was the first agency whose website we reviewed to 
identify the list of drug products for which a recommendation 
met our inclusion criteria: the recommendation had to be for 
an initial submission to the Common Drug Review and it had 
to have been issued between Jan. 1, 2009, and Jan. 1, 2015. 
We chose to compile data for a 6-year range to ensure we 
could include health technology assessment recommendations 
for a sizeable sample of medicines in our analysis and to cap-
ture as many of the subsequent listing decisions by the provin-
cial drug plans as possible. However, if a resubmission was 
submitted up to July 2016 for any of the drug products that 
met the initial inclusion criteria, the latest recommendation 
was recorded. For each eligible medicine, the following data 
were recorded: generic name, proprietary drug name, indica-
tion, date of recommendation and recommendation type 
(positive or negative).
We next searched the websites of the governments of 
Alberta, BC, Ontario and Quebec to find the latest listing deci-
sion (up to Jan. 1, 2015) by the provincial drug plans for each 
of the medicine–indication combinations we identified in the 
first step. Each health technology assessment recommendation 
or provincial listing decision was recorded by proprietary drug 
name and indication and categorized as either a positive or 
negative recommendation/reimbursement decision. A recom-
mendation/decision to reimburse the medicine, even if there 
were restrictions, was considered positive and a recommenda-
tion/decision to not reimburse was considered negative.
The health technology assessment recommendations and 
provincial listing decisions were collected by a single 
researcher (N.A.) to ensure consistency, and an independent 
second expert checked that all relevant data had been appro-
priately recorded.
Statistical analysis
We compared the Common Drug Review recommendations 
with provincial listing decisions to calculate how many were 
aligned. Because the listing decisions differed among prov-
inces, it could be misleading to simply report the total number 
of decisions that were aligned with the recommendations; 
therefore, we calculated the percentage agreement between 
jurisdiction pairs (with each pair consisting of the Common 
Drug Review recommendations and the corresponding listing 
decisions of an individual province) to report the percentage 
of concordant recommendations. We also calculated the 
kappa coefficient because it determines the proportion of 
agreement that could be due to chance and may therefore be a 
more robust measure of agreement.16 For this study, we chose 
the Wilson score method to calculate confidence intervals 
because it is suitable for small n values and will not produce 
confidence intervals with negative values or values greater 
than 100%.17
Results
We identified 174 medicine–indication pairs in CADTH 
Common Drug Review recommendations issued from Jan. 1, 
2009, to Jan. 1, 2015; 110 of these met the inclusion criterion 
of being an initial submission (Appendix 1, available at www.
cmajopen.ca/content/4/4/E674/suppl/DC1). However, the 
latest reimbursement recommendation (issued by the Com-
mon Drug Review up to July 2016) was recorded for compari-
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Among the 110 medicine–indication pairs, listing decisions 
were available for 95 in Alberta, 102 in Quebec, 104 in 
Ontario and 106 in BC (Figure 1). The Common Drug 
Review made negative recommendations for 47.3% of the 
pairs. Each of the 3 provinces that participate in the Common 
Drug Review made negative listing decisions for a smaller 
percentage of pairs, ranging from 31.7% for Ontario to 
45.3% for BC (Table 1, Figure 1). Quebec, which does not 
participate in the Common Drug Review, had the lowest per-
centage of negative decisions (30.4%). The percentage agree-
ment between Common Drug Review recommendations and 
provincial listing decisions or recommendations from Quebec 
was 74.5% for Quebec, 78.8% for Ontario, 78.9% for Alberta 
and 81.1% for BC (Table 2).
The kappa scores for agreement between Common Drug 
Review recommendations and provincial listing decisions 
were 0.62 (95% confidence interval [CI] 0.47–0.77) for BC, 
0.58 (95% CI 0.42–0.74) for Alberta, 0.56 (95% CI 0.41–0.72) 
for Ontario and 0.47 (95% CI 0.31–0.64) for Quebec.
Interpretation
The listing decisions of the provincial drug plans were gen-
erally congruent with the Common Drug Review’s recom-
mendations during the study period. According to a com-
monly cited scale for the interpretation of kappa values,18,19 
the level of agreement between Common Drug Review 
 recommendations and provincial listing decisions can be 
considered substantial for BC and moderate for Alberta, 
Ontario and Quebec.
Price negotiations and other factors can affect the final 
decisions of provincial drug plans about whether or not to list 
a medicine. Manufacturers and provincial payers often negoti-
ate price as a component of product listing agreements, but 
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Figure 1: Number of 110 medicine–indication pairs that received positive and negative reimbursement recommendations by 
the Common Drug Review issued from January 2009 to January 2015. INESSS = Institut national d’excellence en santé et 
en services sociaux.
Table 1: Reimbursement recommendations by the CADTH Common Drug Review and 
listing decisions by 4 provincial drug plans for medicine–indication pairs
Health technology assessment agency  
or provincial payer
Reimbursement recommendation or listing decision;  
% of medicine–indication pairs (95% CI)
Positive* Negative*
CADTH (n = 110) 52.7 (43.5–61.8) 47.3 (38.2–56.5)
Alberta Health (n = 95) 58.9 (48.9–68.3) 41.1 (31.7–51.1)
British Columbia Pharmacare (n = 106) 54.7 (45.2–63.9) 45.3 (36.1–54.8)
Ontario Drug Benefit Plan (n = 104) 68.3 (58.8–76.4) 31.7 (23.6–41.2)
INESSS (Quebec) (n = 102) 69.6 (60.1–77.7) 30.4 (22.3–39.9)
Note: CI = confidence interval, INESSS = Institut national d’excellence en santé et en services sociaux.
*A recommendation/decision to reimburse the medicine, even if there were restrictions, was considered positive and 
a recommendation/decision to not reimburse was considered negative.
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there is wide variation in the negotiating power of the prov-
inces primarily because of their differing population sizes.20 
Price negotiations are a key cause of the lack of congruity 
between Ontario’s listing decisions and the recommendations 
of the Common Drug Review, because Ontario has the larg-
est population in the country and thus the greatest negotiating 
power. Research has also shown Ontario to have the greatest 
proportion of medicines funded through the use of product 
listing agreements.21 The review process in Alberta allows 
manufacturers to negotiate a product listing agreement only 
after a formal decision on the initial price has been reached.22
The recommendations framework of the Common Drug 
Review has evolved over time. In November 2012, CADTH 
made its framework publicly available. The framework 
included a category of “List with criteria and/or conditions” 
for recommendations that may include a condition that the 
price be reduced to lead to a greater likelihood of a positive 
provincial listing decision and accommodate the price negotia-
tions with manufacturers after the Common Drug Review.23 In 
addition, the framework included a category of “Do not list at 
submitted price” that has been used in cases in which the drug 
under review showed a clinical benefit comparable to that of its 
comparator(s) but its cost or cost-effectiveness relative to that 
of its comparator(s) was unacceptable. Before November 2012, 
“Do not list at submitted price” was a subcategory of the “Do 
not list” category. The Common Drug Review does not evalu-
ate budget impact analyses and affordability, and there are no 
explicit willingness-to-pay thresholds.23 Before April 2015, 
product listing agreements could not be negotiated in Quebec 
before a medicine had been included in the list of medicines 
approved for reimbursement.24 The Quebec pricing policy also 
ensures that the province shall not pay more than the lowest 
negotiated price in Canada.25
The pan-Canadian Pharmaceutical Alliance was estab-
lished in 2010 and aims to combine the purchasing power of 
all provinces and territories to negotiate the prices of medi-
cines reviewed by the Common Drug Review or the pan-
Canadian Oncology Drug Review.26 The work of the pan-
Canadian Pharmaceutical Alliance could lead to more 
consistent listing decisions across Canada; however, the par-
ticipating provinces and territories will still have independent 
budgets that will vary in size, and the prices negotiated by the 
pan-Canadian Pharmaceutical Alliance may still be more 
affordable for wealthier provinces.
The results of our study expand previous work and provide 
valuable insights when compared with those of previous stud-
ies with similar methodology. The degree of agreement 
between Common Drug Review reimbursement recommen-
dations and provincial listing decisions was greater in our study 
than in a 2011 study by Gamble and colleagues.6 Gamble and 
colleagues6 calculated agreement between Common Drug 
Review recommendations and the listing decisions of 11 public 
drug plans for all Common Drug Review recommendations 
issued from the inception of the program to May 2009 using 
the binomial categories “listed” and “not listed.” We also used 
a binomial approach to classification. Gamble and colleagues6 
identified Ontario’s public drug plan as having the lowest per-
centage agreement (64.2%) and kappa coefficient (κ  = 0.28) 
with the Common Drug Review recommendations among the 
11 plans they studied. We found that Ontario’s more recent 
listing decisions are in greater agreement with Common Drug 
Review recommendations. The kappa coefficients calculated in 
our study also suggest that there is now greater alignment 
among the provinces in terms of their listing decisions than 
before the inception of the Common Drug Review.27
Other studies have evaluated agreement between provin-
cial listing decisions, but their results are difficult to compare 
with ours because of differing study methodologies. Anis and 
colleagues27 calculated kappa coefficients for provincial listing 
decisions using binomial categories for the 10 provinces by 
directly comparing provinces because the Common Drug 
Review did not exist at the time of their study. They reported 
kappa coefficients ranging from 0.06 to 0.39 for Alberta, BC, 
Ontario and Quebec. The results of MacDonald and Potvin28 
are also difficult to compare with ours because they used “full” 
and “restricted” as the 2 categories for comparison. Morgan 
and colleagues29 used different reimbursement categories and 
did not limit their comparison to new medicines issued a 
reimbursement recommendation by the Common Drug 
Review. Attaran and colleagues5 calculated percentage agree-
ments using a multinomial classification system, a method 
that has been criticized because of the difficulty of accurately 
comparing restrictions.30
Limitations
At the time of data collection, the recommendations and listing 
decisions available on the websites of the Common Drug 
Review and the 4 provinces in the study met our inclusion cri-
teria. However, the Common Drug Review and provincial drug 
plans continue to update their reports and formularies, so these 
results provide an insight into the health technology assessment 
landscape only for a defined period. Because 18 public drug 
plans participate in the Common Drug Review process, the fact 
that we reviewed data from only 3 participating provinces and 
Quebec is a limitation of this study. The evolution of the cate-
gories of recommendations in the Common Drug Review 
framework over time may pose challenges for researchers wish-
ing to examine the agreement between recommendations and 
provincial listing decisions. The drug plans participating in the 
Common Drug Review have varying resources available to 
review new medicines in the context of their population; there-
Table 2: Agreement between Common Drug Review 
reimbursement recommendations and provincial listing 
decisions
Province % agreement κ value (95% CI)
Alberta 78.9 0.58 (0.42–0.74)
British Columbia 81.1 0.62 (0.47–0.77)
Ontario 78.8 0.56 (0.41–0.72)
Quebec 74.5 0.47 (0.31–0.64)
Note: CI = confidence interval.
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fore, the results of our study may not be generalizable to all 18 
participating drug plans. Future studies can build on this 
research by evaluating the concordance between Common 
Drug Review recommendations and listing decisions for all 
participating federal, provincial and territorial drug plans.
Conclusion
Our study showed moderate to substantial agreement 
between provincial listing decisions and Common Drug 
Review reimbursement recommendations. The findings sug-
gest that the Common Drug Review provides value for partic-
ipating drug plans. It could be argued that these observed 
scores of alignment could indicate that the provinces have 
become more reliant on the Common Drug Review over time 
and that the Common Drug Review continues to improve its 
ability to meet payers’ needs. The fact that the provinces are 
able to come to different decisions on the basis of Common 
Drug Review recommendations illustrates the flexibility of the 
process. Provincial payers, which have differing budgets and 
patient populations, can consider their local context in their 
decision-making. The findings of our study could have impli-
cations for other regions with a centralized regulatory author-
ity and a fragmented payer environment, such as Europe. 
Even though European countries are much more heteroge-
neous than Canadian provinces, the Common Drug Review 
provides an example of a centralized review process that gen-
erates evidence to support the common requirements of par-
ticipating plans with the added advantage that each plan can 
incorporate context-specific evidence and budgetary consider-
ations into its decision-making.
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